OGN
Organon & Co.
Drug Manufacturers - General · Healthcare · United States
13.72
close · 2026-08-13
value
93
cheaper than peers93
quality
44
stronger fundamentals44
ranked against
Healthcare
value
quality
374 peerssector comparisonwide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 3.77× | 99 |
| price to sales | 0.58× | 93 |
| EV to EBITDA | 6.90× | 89 |
| price to book | 3.58× | 56 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 34.0% | 92 |
| operating margin | 18.7% | 84 |
| revenue growth | -3.5% | 15 |
| debt to equity | 948.9% | 3 |
4 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | $529.1M |
| employees | 10,000 |
| first trade | 2021-05-14 |
| next earnings | 2026-07-31 |
| fundamentals updated | 2026-07-31 |